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ABSTRACT
Objectives: It is not currently clear whether all
anticoagulated patients with a head injury should
receive CT scanning or only those with evidence of
traumatic brain injury (eg, loss of consciousness or
amnesia). We aimed to determine the cost-
effectiveness of CT for all compared with selective CT
use for anticoagulated patients with a head injury.
Design: Decision-analysis modelling of data from a
multicentre observational study.
Setting: 33 emergency departments in England and
Scotland.
Participants: 3566 adults (aged ≥16 years) who had
suffered blunt head injury, were taking warfarin and
underwent selective CT scanning.
Main outcome measures: Estimated expected
benefits in terms of quality-adjusted life years
(QALYs) were the entire cohort to receive a CT scan;
estimated increased costs of CT and also the
potential cost implications associated with patient
survival and improved health. These values were used
to estimate the cost per QALY of implementing a
strategy of CT for all patients compared with
observed practice based on guidelines recommending
selective CT use.
Results: Of the 1420 of 3534 patients (40%) who
did not receive a CT scan, 7 (0.5%) suffered a
potentially avoidable head injury-related adverse
outcome. If CT scanning had been performed in all
patients, appropriate treatment could have gained
3.41 additional QALYs but would have incurred
£193 149 additional treatment costs and £130 683
additional CT costs. The incremental cost-
effectiveness ratio of £94 895/QALY gained for
unselective compared with selective CT use is
markedly above the threshold of £20–30 000/QALY
used by the UK National Institute for Care Excellence
to determine cost-effectiveness.
Conclusions: CT scanning for all anticoagulated
patients with head injury is not cost-effective compared
with selective use of CT scanning based on guidelines
recommending scanning only for those with evidence
of traumatic brain injury.
Trial registration number: NCT 02461498.
BACKGROUND
It is estimated that at least 1% of the UK
population are taking an anticoagulant, such
as warfarin, increasing to 8% in those aged
80 years and over.1 2 People taking an anti-
coagulant who experience a head injury are
at an increased risk of intracranial haemor-
rhage,3 4 with rates of mortality reported
between 45% and 70%.3 5–7 Liberal use of
CT scanning is therefore required to identify
intracranial haemorrhage in these patients.
However, it is not clear whether all anticoa-
gulated patients with head injury should
receive a CT scan or whether CT should be
used selectively and limited to those with evi-
dence of traumatic brain injury, such as
those with loss of consciousness or amnesia.8
Management of head injury in the UK
follows guidance from the National Institute
for Health and Care Excellence (NICE).
NICE guidance issued in 20079 recom-
mended that patients with coagulopathy
(including those currently treated with war-
farin) should undergo CT scanning only if
they report amnesia or loss of consciousness
following injury. Updated guidance issued in
Strengths and limitations of this study
▪ This is the largest study to model options for the
clinical management of anticoagulated patients
taking warfarin with a head injury.
▪ The methods used to estimate health gain from
treating additional cases detected by universal
CT scanning are transparent and reproducible,
and were robust to the sensitivity analyses
undertaken.
▪ Some patients who suffered adverse outcome
may not have been identified on follow-up poten-
tially being a limitation of the study, leading to
underestimation of the potential benefit of CT
scan for all patients.
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201410 recommended that all patients having warfarin
treatment should undergo CT scanning regardless of
whether they reported amnesia or loss of consciousness
(figure 1). The new guidance should increase the
number of scans performed and intracranial injuries
identified, but it is not clear whether the benefits of this
approach justify the costs of additional CT scanning.
The AHEAD study was an observational cohort study
of patients with head injury who were taking warfarin
and presented to a hospital emergency department
(ED) (S Mason, M Kuczawski, MD Teare, et al. The
AHEAD study: an evaluation of the management of
anticoagulated patients who suffer head injury. UK;
2016. Unpublished). It was undertaken when NICE 2007
guidance was in operation but before NICE 2014 guid-
ance was issued. We aimed to use data from the AHEAD
study and decision analysis modelling to determine the
cost-effectiveness of CT for all compared with observed
practice based on guidelines recommending selective
CT for those with evidence of traumatic brain injury.
METHODS
The methods for the AHEAD study are described in
detail elsewhere (S Mason et al. 2016. Unpublished).
Briefly, 3566 adults who were taking warfarin and
attended the ED of 33 hospitals in England and
Scotland between September 2011 and March 2013
following head injury were recruited. Research staff in
hospital sites recorded basic demographic information,
attendance details, injury mechanism, clinical
examination findings and CT results. Patients were then
followed up to 10 weeks after presentation using hospital
record review and postal questionnaire.
We identified all patients with an adverse outcome
who had not received a CT scan at their initial hospital
attendance. The patients that did receive a CT scan
(under a selective CT scanning policy) would receive the
same treatment if a CT scan all policy was in place;
therefore, it is the former group of patients who would
be expected to receive clinical benefit from a policy of
CT scanning all patients. However, a threshold analysis
was conducted to estimate the proportion of inpatient
attendances of <48 hours that would need to be avoided
for the CT scan all policy to have a cost per
quality-adjusted life year (QALY) below £30 000, assum-
ing the cost of such an inpatient stay to be that asso-
ciated with a non-elective inpatient stay (£615).11 An
adverse outcome was defined as: death; neurosurgery;
positive CT scan finding; or reattendance to the hospital
with a significant head injury-related complication up to
10 weeks after the original attendance. These reatten-
dances were confirmed following the review of hospital
records and CT scan results, where undertaken.
Decision analysis modelling was used to estimate the
incremental QALYs and costs had those patients with an
adverse outcome that were not CT scanned received a
CT scan on initial hospital attendance. Different
assumptions were required for patients conditional on
whether they survived the adverse event. For patients
who died, assumptions were required regarding: the
probability of survival if a CT scan had been performed;
the Glasgow Outcome Scale (GOS) state to which the
patient would be categorised if they survived;12 and the
cost of neurosurgery. For patients who survived, an
assumption was required relating to the probability of
GOS increase if a CT scan had been performed.
Regardless of survival outcome, assumptions were
Figure 1 NICE guidance 2007
versus 2014.
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required on: the life expectancy of a person with the
same gender and age profile; the costs and utility asso-
ciated with each GOS state; and the cost of a CT scan.
The assumptions used within the model are detailed
below. The results presented take an English and
Scottish perspective and use direct healthcare and per-
sonal social services costs.
Model assumptions
For patients who did not survive the adverse event:
▸ The probability of survival if a CT scan had been performed:
Two clinicians provided estimates of the probability of
survival had the patient received a CT scan. In the
main analysis, an average value was used, although
sensitivity analyses were undertaken, assuming that
each clinician was correct.
▸ The GOS state to which the patient would be categorised if
they survived: A single clinician provided an estimate
of the GOS of the patient if they had survived. In a
sensitivity analysis, the impact of the GOS state being
one level higher (ie, more favourable to the patient)
was explored.
▸ The costs of neurosurgery: The cost of neurosurgery was
assumed to be that associated with the weighted
average of NHS Reference Cost Codes AA50A–
AA57B, excluding codes relating to patients aged
18 years and under, which was £3994.13 It was
assumed that all patients who died without having a
CT scan would undergo neurosurgery.
For patients who survived the adverse event:
▸ The probability of GOS increase if a CT scan had been per-
formed: Two clinicians provided estimates of the prob-
ability of an increase in the GOS level (ie, a better
patient outcome), if a CT scan had been performed.
In the main analysis, an average value was used,
although sensitivity analyses were undertaken, assum-
ing that each clinician was correct.
For all patients:
▸ The life expectancy of the person: These data were taken
from UK Life Tables,14 and it was assumed that these
were not affected by an adverse event that had been
survived.
▸ The costs and utility associated with each GOS state: The
data for GOS states 2–4 were taken from Pandor
et al15 with costs inflated from 2008/2009 values to
2014/2015 prices using hospital and community
health services indices reported in Curtis and
Burns.11 The resultant values are provided in table 1.
For GOS state 5, it was assumed that the UK general
population utility conditional on age and sex was
appropriate which was taken from Ara and Brazier.16
▸ The cost of a CT scan: The cost of a CT scan was
assumed to be that associated with NHS Reference
Cost Code RD20A, which was £92.
▸ The mathematical model: The model calculated the
expected difference in costs and QALYs of moving
from observed practice to a strategy of CT scanning
all patients. The following formulae were used in cal-
culating the cost and QALY impacts associated with
provided CT scans to patients with adverse events who
did not receive a CT scan. All values were discounted
at 3.5% per annum in accordance with NICE guide-
lines.17 A lifetime horizon was assumed due to poten-
tial mortality benefits of the CT all strategy.
For patients who did not survive:
▸ Change in costs: Average probability of survival if CT
scan performed×(life expectancy×cost per year in esti-
mated GOS state+cost of neurosurgery).
▸ Change in QALYs: Average probability of survival if CT
scan performed×(life expectancy×utility per year in
estimated GOS state).
For patients who did survive:
▸ Change in costs: Average probability of GOS increase if
CT scan performed×life expectancy×(cost per year in
higher GOS state–cost per year in lower GOS state).
▸ Change in QALYs: Average probability of GOS increase
if CT scan performed×(life expectancy×utility per
year in higher GOS state–utility per year in lower
GOS state)
RESULTS
Follow-up data were available for 3534 of 3566 patients
(99%) in the AHEAD cohort. Details of the cohort are
published (S Mason et al. 2016. Unpublished). Glasgow
Outcome Scale and diagnosis was available for 91.4%
(n=3229) and 99.9% (n=3530) patients, respectively.
Overall, 2114 out of 3534 patients (60%) received a CT
scan. Of the 1420 patients without a CT scan, 728 (51%)
were admitted to hospital, 20 (1.4%) had subsequent
head injury-related hospital attendances and 74 (5.2%)
died during follow-up. Cause of death was head
injury-related in 4 (0.3%), unrelated in 52 (3.7%) and
unknown in 19 (1.3%). Adverse outcomes were identi-
fied in 7 of 1420 (0.5%) patients who did not have CT
scan: 4 deaths and 3 with a related further hospital
Table 1 Assumed costs and utility associated with each Glasgow Outcome Scale state, and assumed cost of neurosurgery
GOS state One-off cost (£) Annual costs (£) Utility value Source
2 47 674 46 595 0.00 Pandor et al15 with costs inflated using Curtis
and Burns113 0 37 214 0.15
4 18 837 0 0.51
5 0 0 Population value* Assumption
*The utility in GOS state 5 were estimated from Ara and Brazier16 conditional on age and sex.
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attendance and significant finding on CT scan at
reattendance.
The estimated changes in costs and QALYs per indi-
vidual patient are provided in table 2. The summarised
analyses including the increased costs of CT scans are
provided in table 3.
It is estimated that the cost per QALY gained through
providing a CT scan is in excess of £90 000 per QALY
which is markedly greater than the £20 000–£30 000 per
QALY gained threshold reported by NICE.17 This con-
clusion did not alter within the sensitivity analyses per-
formed. Using the estimates from the individual expert
clinicians which produced values of £90 659 and £99 547
per QALY gained or if the cost of neurosurgery was not
included for the patient who neither expert clinician
believed would have survived even with a CT scan
(£93 725 per QALY gained). When it was assumed that
all patients survived at one GOS state better than esti-
mated in the base case, the cost per QALY gained
reduced to £36 864 (an additional £213 139 to obtain
5.78 QALYs) but still did not fall below NICE thresholds.
It was estimated that over 67% of the 537 inpatient
stays of <48 hours observed would need to be avoided in
order for the CT scan all policy to have a cost per QALY
of <£30 000.
DISCUSSION
Follow-up of 1420 patients who did not have a CT scan
in the AHEAD cohort identified seven cases (four
deaths, three delayed diagnoses) that might have been
identified by CT scanning at initial hospital attendance.
Decision analytic modelling showed that appropriate
treatment of these cases could have gained 3.41 QALYs
but would have incurred £193 149 additional treatment
costs and £130 683 additional costs for CT scanning.
This produces an incremental cost of £94 895 per QALY
gained, which is greatly above the usual threshold of
£20–30 000/QALY that NICE uses to determine cost-
effectiveness. Our analysis therefore suggests that CT for
all anticoagulated patients with head injury, as recom-
mended in NICE 2014 guidance, is not cost-effective
compared with the selective use of CT scanning
observed in practice when NICE 2007 guidance was in
operation.
Our analysis has a number of strengths and weak-
nesses. It was based on a large representative cohort of
patients who presented to a wide range of hospitals. The
methods used to estimate health gain from treating add-
itional cases detected by universal CT scanning are trans-
parent and reproducible, and were robust to the
sensitivity analyses undertaken. A potential limitation is
that some patients who suffered adverse outcome may
not have been identified on follow-up, leading to under-
estimation of the potential benefit of CT scan for all
patients. However, it is worth noting that 10.79 QALYs
would be required to reach the NICE threshold of
£30 000/QALY for cost-effectiveness, so our conclusion
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regarding the lack of cost-effectiveness of unselective CT
scanning would only be undermined if follow-up had
identified <1 in 3 patients with adverse events. This
seems extremely unlikely.
It is not believed that the threshold level for avoiding
inpatient admissions of <48 hours would be plausible.
Owing to the age and comorbidities of this cohort of
patients, there will be many reasons for patients being
admitted irrespective of whether a CT scan was per-
formed. These reasons may be head injury-related such
as observation, but are also likely to include other
reasons such as intercurrent infections, injuries relating
to attendance (other than the head injury) and for
social reasons. Additionally, one could also postulate that
by detecting incidental findings, the additional CT scans
could result in additional admissions. If so, the incre-
mental costs of the CT all strategy would increase and it
would become less cost-effective. We have no data to
determine whether additional CT scans result in more
or fewer admissions.
Most international guidance, including the National
Emergency X-Radiology Utilisation Study (NEXUS II),
CT in Head Injury Patients (CHIP), American College
of Emergency Physicians (ACEP) head CT and the
European Federation of Neurological Societies
(EFNS),18–21 advocate that all patients taking warfarin
should have an immediate CT scan irrespective of injury
severity, GCS or neurological symptoms. The UK guide-
lines (NICE) are based on the Canadian CT Head Rule
(CCHR),22 which excluded patients taking warfarin and
up until January 2014, stated that a CT scan should be
performed on patients taking warfarin if the patient pre-
sented with loss of consciousness or amnesia. These
guidelines have now been updated to recommend all
anticoagulated patients receive a CT scan, but no new
evidence appears to have been published to support this
recommended change in practice. Our analysis suggests
that the 2014 revision to NICE guidance has resulted in
less cost-effective care.
Previous literature investigating the patient outcomes
and costs associated with diagnosing and treating head-
injured patients who are taking anticoagulants are
limited and difficult to compare with our analysis.
Several recent studies have used decision analysis model-
ling to estimate the costs and benefits of CT scanning in
the general (ie, non-anticoagulated) head-injured popu-
lation23–25 and have generally shown that using a clinical
decision rule to select patients for CT scanning is more
cost-effective than unselective CT scanning. The only
study identified that focused solely on anticoagulated
patients was undertaken by Li in 2012.26 Li questioned
how this cohort of patients should be managed due to
the nature of delayed complications associated with anti-
coagulant use, while also considering the costs attached
to CT imaging and admittance to hospital. The analyses
were based on data taken from other studies and
included repeated CT scans (2) and 24-hour admission
per patient. The costs per year of a life saved in the
USA, Spain and Canada were estimated as $1 million,
$158 000 and $105 000, respectively.
Future research is needed to validate our findings on
the potential benefits, harms and costs of CT scanning
since the introduction of NICE 2014, in addition to
further work on the criteria used for deciding whether a
CT scan is appropriate such as the use of serum protein
biomarkers.
CONCLUSION
CT scanning for all anticoagulated patients with head
injury is not cost-effective compared with selective use of
CT scanning based on guidelines recommending scan-
ning only for those with evidence of traumatic brain
injury. A move (or return) to selective use of CT scan-
ning would substantially reduce healthcare costs with
only a small increase in potentially avoidable adverse
outcomes.
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Table 3 The comparison of CT all with observed practice
Change in costs
from CT scanning (£)
Change in QALYs
from CT scanning
ICER (cost per QALY
gained (£))
Changes in individual patient values 193 149 3.41
Additional CT scanning costs 130 683
Net values 323 832 3.41 94 895
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